跳至主要内容
临床试验/NCT00672074
NCT00672074已完成2 期

A Phase II, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety and Efficacy of Ipamorelin Compared to Placebo for the Management of Post-Operative Ileus in Patients

Helsinn Therapeutics (U.S.), Inc19 个研究点 分布在 1 个国家目标入组 117 人开始时间: 2008年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
117
试验地点
19
主要终点
Recovery of GI function

研究概览

简要总结

The purpose of this study is to determine if ipamorelin is safe and effective in the management of post-operative ileus.

详细描述

The safety and efficacy of ipamorelin in the management of post-operative ileus

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • willing to comply with protocol
  • undergoing bowel resection surgery
  • ASA Class I-III
  • Females must not be pregnant
  • Body weight 40-150 kg

排除标准

  • mentally incompetent or unable to provide informed consent
  • clinically unstable
  • significant liver disease
  • clinically significant lab or EKG abnormalities
  • alcohol or illicit drug abuse
  • history of or current surgery that would prevent proper evaluation of safety or efficacy of drug

研究组 & 干预措施

1 Ipamorelin

Active Comparator

干预措施: Ipamorelin (Drug)

2 Placebo

Placebo Comparator

干预措施: placebo (Drug)

结局指标

主要结局

Recovery of GI function

时间窗: Until hospital discharge

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (19)

Loading locations...

相似试验

Safety and Efficacy of Ipamorelin for Management of... | 临床试验